Autoinflammationssyndrome – kutane Manifestationen

Schlüsselwörter

Autoinflammationssyndrome - schubweises Auftreten - Inflammasom - proinflammatorische Zytokine

Keywords

autoinflammatory syndromes - batch-wise appearance - inflammasome - pro-inflammatory cytokines

• Literatur

• 1 Aguado Gil L, Irarrazaval-Armendáriz I, Pretel-Irazabal M. Advances in the diagnosis and treatment of tumor necrosis factor receptor-associated periodic syndrome. Actas Dermosifiliogr 2013; 104: 617-622
• 2 Arostegui JI, Aldea A, Modesto C et al. Clinical and genetic heterogeneity among Spanish patients with recurrent autoinflammatory syndromes associated with the CIAS1/PYPAF1/NALP3 gene. Arthritis Rheum 2004; 50: 4045-4050
• 3 Arostegui JI, Arnal C, Merino R et al. NOD2 gene-associated pediatric granulomatous arthritis: clinical diversity, novel and recurrent mutations, and evidence of clinical improvement with interleukin-1 blockade in a Spanish cohort. Arthritis Rheum 2007; 56: 3805-3813
• 4 Ben Abdelghani K, Dran DG, Gottenberg JE et al. Tumor necrosis factor-alpha blockers in SAPHO syndrome. J Rheumatol 2010; 37: 1699-1704
• 5 Brenner M, Ruzicka T, Plewig G et al. Targeted treatment of pyoderma gangrenosum in PAPA (pyogenic arthritis, pyoderma gangrenosum and acne) syndrome with the recombinant human interleukin-1 receptor antagonist anakinra. Br J Dermatol 2009; 161: 1199-1201
• 6 Cattalini M, Meini A, Monari P et al. Recurrent migratory angioedema as cutaneous manifestation in a familiar case of TRAPS: dramatic response to Anakinra. Dermatol Online J 2013; 19: 20405
• 7 Contassot E, Beer HD, French LE. Interleukin-1, inflammasomes, autoinflammation and the skin. Swiss Med Wkly 2012; 142: w13590
• 8 Cortis E, De Benedetti F, Insalaco A et al. Abnormal production of tumor necrosis factor (TNF) – alpha and clinical efficacy of the TNF inhibitor etanercept in a patient with PAPA syndrome [corrected]. J Pediatr 2004; 145: 851-855
• 9 Demidowich AP, Freeman AF, Kuhns DB et al. Brief report: genotype, phenotype, and clinical course in five patients with PAPA syndrome (pyogenic sterile arthritis, pyoderma gangrenosum, and acne). Arthritis Rheum 2012; 64: 2022-2027
• 10 Dierselhuis MP, Frenkel J, Wulffraat NM et al. Anakinra for flares of pyogenic arthritis in PAPA syndrome. Rheumatology (Oxford) 2005; 44: 406-408
• 11 Federici S, Caorsi R, Gattorno M. The autoinflammatory diseases. Swiss Med Wkly 2012; 142: w13602
• 12 Feldmeyer L, Werner S, French LE et al. Interleukin-1, inflammasomes and the skin. Eur J Cell Biol 2010; 89: 638-644
• 13 Galeazzi M, Gasbarrini G, Ghirardello A et al. Autoinflammatory syndromes. Clin Exp Rheumatol 2006; 24 (Suppl. 40) S79-85
• 14 Hashkes PJ, Toker O. Autoinflammatory syndromes. Pediatr Clin North Am 2012; 59: 447-470
• 15 Hawkins PN, Lachmann HJ, McDermott MF. Interleukin-1-receptor antagonist in the Muckle-Wells syndrome. N Engl J Med 2003; 348: 2583-2584
• 16 Hayem G, Bouchaud-Chabot A, Benali K et al. SAPHO syndrome: a long-term follow-up study of 120 cases. Semin Arthritis Rheum 1999; 29: 159-171
• 17 Just A, Adams S, Brinkmeier T et al. P Successful treatment of primary chronic osteomyelitis in SAPHO syndrome with bisphosphonates. J Dtsch Dermatol Ges 2008; 6: 657-660
• 18 Kastner DL, Aksentijevich I, Goldbach-Mansky R. Autoinflammatory disease reloaded: a clinical perspective. Cell 2010; 140: 784-790
• 19 Kim CH, Kadhim S, Julien C. Treatment of Pain in SAPHO (Synovitis, Acne, Pustulosis, Hyperostosis, and Osteitis) Syndrome. PM R 2014; 6: 92-95
• 20 Kone-Paut I, Galeotti C. Anakinra for cryopyrin-associated periodic syndrome. Expert Rev Clin Immunol 2014; 10: 7-18
• 21 Kuemmerle-Deschner JB, Haug I. Canakinumab in patients with cryopyrin-associated periodic syndrome: an update for clinicians. Ther Adv Musculoskelet Dis 2013; 5: 315-329
• 22 Lachmann HJ, Lowe P, Felix SD et al. In vivo regulation of interleukin 1beta in patients with cryopyrin-associated periodic syndromes. J Exp Med 2009; 206: 1029-1036
• 23 Nestle FO, Di Meglio P, Qin JZ et al. Skin immune sentinels in health and disease. Nature reviews. Immunology 2009; 9: 679-691
• 24 Nguyen MT, Borchers A, Selmi C et al. The SAPHO syndrome. Semin Arthritis Rheum 2012; 42: 254-265
• 25 Obici L, Meini A, Cattalini M et al. Favourable and sustained response to anakinra in tumour necrosis factor receptor-associated periodic syndrome (TRAPS) with or without AA amyloidosis. Ann Rheum Dis 2011; 70: 1511-1512
• 26 Punzi L, Furlan A, Podswiadek M et al. Clinical and genetic aspects of Blau syndrome: a 25-year follow-up of one family and a literature review. Autoimmun Rev 2009; 8: 228-232
• 27 Rose CD, Wouters CH, Meiorin S et al. Pediatric granulomatous arthritis: an international registry. Arthritis Rheum 2006; 54: 3337-3344
• 28 Salles M, Olive A, Perez-Andres R et al. The SAPHO syndrome: a clinical and imaging study. Clin Rheumatol 2011; 30: 245-249
• 29 Schmaltz R, Vogt T, Reichrath J. Skin manifestations in tumor necrosis factor receptor-associated periodic syndrome (TRAPS). Dermatoendocrinol 2010; 2: 26-29
• 30 Schroder K, Tschopp J. The inflammasomes. Cell 2010; 140: 821-832
• 31 Sfriso P, Caso F, Tognon S et al. Blau syndrome, clinical and genetic aspects. Autoimmun Rev 2012; 12: 44-51
• 32 Smith EJ, Allantaz F, Bennett L et al. Clinical, Molecular, and Genetic Characteristics of PAPA Syndrome: A Review. Curr Genom 2010; 11: 519-527
• 33 Snyers B, Dahan K. Blau syndrome associated with a CARD15/NOD2 mutation. Am J Ophthalmol 2006; 142: 1089-1092
• 34 Stichweh DS, Punaro M, Pascual V. Dramatic improvement of pyoderma gangrenosum with infliximab in a patient with PAPA syndrome. Pediatr Dermatol 2005; 22: 262-265
• 35 Toro JR, Aksentijevich I, Hull K et al. Tumor necrosis factor receptor-associated periodic syndrome: a novel syndrome with cutaneous manifestations. Arch Dermatol 2000; 136: 1487-1494
• 36 Vaitla PM, Radford PM, Tighe PJ et al. Role of interleukin-6 in a patient with tumor necrosis factor receptor-associated periodic syndrome: assessment of outcomes following treatment with the anti-interleukin-6 receptor monoclonal antibody tocilizumab. Arthritis Rheum 2011; 63: 1151-1155
• 37 van Duist MM, Albrecht M, Podswiadek M et al. A new CARD15 mutation in Blau syndrome. Eur J Hum Genet 2005; 13: 742-747
• 38 Wendling D, Prati C, Aubin F. Anakinra treatment of SAPHO syndrome: short-term results of an open study. Ann Rheum Dis 2012; 71: 1098-1100
• 39 Yasui K, Yashiro M, Tsuge M et al. Thalidomide dramatically improves the symptoms of early-onset sarcoidosis/Blau syndrome: its possible action and mechanism. Arthritis and Rheum 2010; 62: 250-257
• 40 Yu JR, Leslie KS. Cryopyrin-associated periodic syndrome: an update on diagnosis and treatment response. Curr Allergy Asthma Rep 2011; 11: 12-20